NeuroMetrix
NeuroMetrix is a US medical device company that develops the FDA-authorized Quell wearable neuromodulation platform for chronic pain and fibromyalgia management. It serves over 5 million cumulative users globally via direct-to-consumer sales of devices and recurring proprietary consumables, and is now a wholly-owned subsidiary of electroCore, Inc.
- Company typePrivate
- Founded1996
- HeadquartersWoburn, United States
- Headcount101–250
- GTM typeB2C
- OfferingHardware or Manufacturing
What NeuroMetrix does
NeuroMetrix is a US-based medical device company founded in 1996 that develops and commercializes non-invasive wearable neuromodulation devices for chronic pain management and neurological disorders. The company pioneered the concept of automated nerve testing and introduced the Quell platform, billed as the first wearable nerve stimulator for managing chronic pain. Its flagship commercial product is the Quell Fibromyalgia device, an advanced wearable neuromodulator described as the first and only FDA-authorized medical device for reducing fibromyalgia symptoms.
The company's core technology is a cloud-enabled wearable neuromodulation platform that delivers non-invasive nerve stimulation to reduce chronic pain signals, paired with proprietary consumable electrode pads required for ongoing device use. NeuroMetrix markets a focused product portfolio consisting of the Quell hardware line and proprietary aftermarket consumables; according to the company, the majority of its revenue is generated from recurring aftermarket consumable sales, establishing a razor/blade model over its installed base of more than 5 million cumulative users worldwide.
NeuroMetrix sells directly to consumers through its own website with phone and email customer support, primarily targeting chronic pain patients, fibromyalgia patients, and users managing diabetic peripheral neuropathy. Since December 2024, NeuroMetrix has operated as a wholly-owned subsidiary of electroCore, Inc. (NASDAQ: ECOR), continuing to provide Quell products and services under its established brand while sharing electroCore's corporate office in Rockaway, New Jersey. The strategic rationale for the acquisition is to integrate NeuroMetrix's wearable neuromodulation platform into electroCore's non-invasive bioelectronic therapy portfolio, expanding combined reach into the broader chronic pain and neurological disorder markets.
NeuroMetrix firmographics
Firmographics- Name
- NeuroMetrix
- Legal name
- NeuroMetrix, Inc.
- Website
- https://neurometrix.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- NeuroMetrix is a US medical device company that develops the FDA-authorized Quell wearable neuromodulation platform for chronic pain and fibromyalgia management. It serves over 5 million cumulative users globally via direct-to-consumer sales of devices and recurring proprietary consumables, and is now a wholly-owned subsidiary of electroCore, Inc.
- Ownership category
- akta.pro rank
NeuroMetrix industry classification
Industry- Product category
- Wearable Neuromodulation Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB)
- akta.pro secondary industries
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK), Posture, Musculoskeletal & Pain-Relief Devices (Posture Trainers, TENS/EMS, Massage Devices) (CRACAQAK)
Keywords
Where NeuroMetrix is headquartered
LocationHeadquarters
- HQ city
- Woburn
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NeuroMetrix business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Quell Device Hardware Sales: Sale of wearable neuromodulation devices (Quell, Quell Fibromyalgia) to patients and consumers for at-home chronic pain management.
- Proprietary Consumables (Aftermarket): Majority of revenue generated from aftermarket sales of proprietary consumables (electrode pads, accessories) required for ongoing use of the Quell devices.
Distribution channels1 record
Marketing channels2 records
NeuroMetrix product offering
Product offeringCore offering
NeuroMetrix develops and globally commercializes non-invasive wearable medical devices for the diagnosis and treatment of pain and neurological disorders. Its flagship offering is the Quell wearable neuromodulation platform, including the Quell Fibromyalgia device — the first and only FDA-authorized medical device for reducing fibromyalgia symptoms — together with proprietary electrode consumables required for ongoing device use.
Product overview
NeuroMetrix offers a focused product portfolio centered on its Quell® wearable neuromodulation platform. The core product is the Quell® Fibromyalgia device, an FDA-authorized wearable neuromodulator for chronic pain and fibromyalgia symptom management. The company also develops proprietary consumables that work with its devices, with consumable aftermarket sales representing the majority of revenue. In December 2024, NeuroMetrix became a wholly-owned subsidiary of electroCore, Inc., and continues to operate under its established Quell brand.
Differentiator
Problem solved
Functional benefit
Brands
- Quell: Quell is NeuroMetrix's cloud-enabled wearable neuromodulation platform for chronic pain management and fibromyalgia treatment. It is the first and only FDA authorized medical device that helps reduce the symptoms of fibromyalgia.
Products and services
- Quell Fibromyalgia
Quantifiable outcome
- Over 5 million people worldwide have benefited from NeuroMetrix healthcare products
Companies that use NeuroMetrix
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
NeuroMetrix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
NeuroMetrix partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- electroCore, Inc.coreIn December 2024 or May 2025 (sources conflict on exact date), electroCore acquired NeuroMetrix as a wholly-owned subsidiary to expand its neurotechnology offerings and integrate NeuroMetrix's cloud-enabled wearable neuromodulation platform. The acquisition enhanced electroCore's non-invasive bioelectronic therapy portfolio with NeuroMetrix's Quell system for chronic pain management and fibromyalgia treatment.
Scale indicators4 records
Recent moves5 records
Expansion highlights4 records
NeuroMetrix competitors and assessment
Company assessmentBroad incumbents
- electroCore: Parent company of NeuroMetrix; commercializes gammaCore, a non-invasive vagus nerve stimulation device for migraine and cluster headache. Directly comparable non-invasive bioelectronic therapy platform with overlapping payer, prescriber, and patient engagement models.
- Nevro: Medical device company commercializing the Senza spinal cord stimulation (SCS) system for chronic pain, including 10 kHz HF therapy. Operates in the same neuromodulation category as NeuroMetrix, with a physician-implanted (rather than wearable) approach.
- Medtronic: Global medical device leader with broad neuromodulation portfolio (Activa DBS, Intellis SCS, Vanta PCNS, InterStim sacral nerve stimulation). Competes for the same chronic pain, neurological disorder, and movement disorder patient populations as NeuroMetrix via implanted systems.
- Abbott: Diversified medical device company with the Proclaim XR family of SCS systems and dorsal root ganglion (DRG) stimulation for chronic pain. Comparable neuromodulation modality addressing the same chronic pain patient pool as Quell.
- Boston Scientific: Operates a large neuromodulation franchise (Precision Spectra WaveWriter SCS, Vercise DBS, Axonics sacral neuromodulation, and recently acquired Neuromodulation Solutions). Competes across the neuromodulation spectrum that NeuroMetrix addresses for chronic pain.
- Inspire Medical Systems: Develops the Inspire hypoglossal nerve stimulation implant for obstructive sleep apnea. Comparable neurostimulation business model with a hardware-plus-accessory consumable structure and physician-channel reimbursement-driven demand.
Direct peers
- Cala Health: Developer of Cala Trio, a wearable TENS device for essential tremor and now chronic disease indications. Closest comparable wearable, non-invasive, prescription-or-DTC neurostimulation platform with a similar consumables-based recurring revenue model.
- SPR Therapeutics: Pioneer in peripheral nerve stimulation (PNS) systems such as the Sprint PNS System for chronic and acute pain. Comparable neuromodulation platform targeting overlapping chronic pain and post-surgical pain indications, though delivered via minimally-invasive percutaneous leads.
Emerging players
- DyAnsys: Developer of wearable neurostimulation devices including DrugRelief for post-operative pain and anxiety relief. Closely comparable form factor (wearable, non-invasive electrical nerve stimulation) and similar indication overlap in chronic pain.
- Hinge Health: Digital musculoskeletal care platform combining virtual PT, wearable sensors (Enso), and AI-guided exercise programs for chronic back and joint pain. Competes with Quell for the same chronic pain patient population via a non-device, software-led alternative.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
NeuroMetrix social profiles
Digital presenceNeuroMetrix financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuroMetrix leadership team
Management profileNumber of profiles
Profiles6 records
NeuroMetrix funding detail
Funding detailFunding overview
Funding rounds7 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuroMetrix M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuroMetrix
What does NeuroMetrix do?
NeuroMetrix develops and globally commercializes non-invasive wearable medical devices for the diagnosis and treatment of pain and neurological disorders. Its flagship offering is the Quell wearable neuromodulation platform, including the Quell Fibromyalgia device — the first and only FDA-authorized medical device for reducing fibromyalgia symptoms — together with proprietary electrode consumables required for ongoing device use.
Is NeuroMetrix a public or private company?
NeuroMetrix is a private company. It is classified as corporate owned and is currently acquired.
When was NeuroMetrix founded?
NeuroMetrix was founded in 1996. It employs 101 to 250 people.
Where is NeuroMetrix based?
NeuroMetrix is headquartered in Woburn, United States, in the North America region.
How does NeuroMetrix make money?
Two revenue lines are on record. Quell Device Hardware Sales are the primary driver. The others are proprietary Consumables (Aftermarket).
Who are NeuroMetrix's main competitors?
Broad incumbents on record are electroCore, Nevro, Medtronic, Abbott, Boston Scientific and Inspire Medical Systems. Direct peers are Cala Health and SPR Therapeutics. Emerging players are DyAnsys and Hinge Health.
Does NeuroMetrix have an API?
No public API is recorded for NeuroMetrix.
What industry is NeuroMetrix in?
NeuroMetrix's product category is Wearable Neuromodulation Medical Devices. Its primary akta.pro industry code is HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables), with a secondary code of HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS). Its NAICS code is 334510 and its SIC code is 3845.